Year Founded
2018
Ownership
Private
Employees
~50
Stage
Preclinical
Modalities
Atmo Biosciences General Information
Developing an ingestible gas-sensing capsule that measures gases directly at source of production in GI tract. Currently conducting pivotal clinical studies for FDA submission for GI motility assessment.
Drug Pipeline
No pipeline data available
Key Partnerships
Otsuka Pharmaceutical
Atmo Biosciences Funding
No funding data available
To view Atmo Biosciences's complete valuation and funding history, request access »
Atmo Biosciences Investors
Breakthrough Victoria
Investor Type: Venture Capital
Holding: Minority
Otsuka Holdings
Investor Type: Venture Capital
Holding: Minority
AusBiotech
Investor Type: Venture Capital
Holding: Minority
You're viewing 3 of 6 investors. Get the full list »